Forte Biosciences (FBRX) Asset Utilization Ratio (2018 - 2019)
Forte Biosciences (FBRX) posted quarterly Asset Utilization Ratio of 0.0 for Q4 2019, down 99.51% year-over-year from 0.19 in Q4 2018, and up 98.94% quarter-over-quarter from 0.0 in Q3 2019.
Forte Biosciences (FBRX) Asset Utilization Ratio (2018 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Asset Utilization Ratio for 2 consecutive years, with 0.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Asset Utilization Ratio fell 99.51% year-over-year to 0.0; the TTM figure through Dec 2019 stood at 0.0 (down 99.51% YoY), while the FY2019 annual figure was 0.0, down 99.65% from the prior year.
- Asset Utilization Ratio improved to 0.0 in Q4 2019 per FBRX's latest filing, from 0.0 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.2 in Q3 2018 and bottomed at 0.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.00 |
| Jun 30, 2019 | 0.20 |
| Mar 31, 2019 | 0.18 |
| Dec 31, 2018 | 0.19 |
| Sep 30, 2018 | 0.20 |
| Jun 30, 2018 | 0.00 |
| Mar 31, 2018 | 0.00 |